CN106967042B - 依利格鲁司他的合成方法及其中间体化合物 - Google Patents

依利格鲁司他的合成方法及其中间体化合物 Download PDF

Info

Publication number
CN106967042B
CN106967042B CN201710169305.9A CN201710169305A CN106967042B CN 106967042 B CN106967042 B CN 106967042B CN 201710169305 A CN201710169305 A CN 201710169305A CN 106967042 B CN106967042 B CN 106967042B
Authority
CN
China
Prior art keywords
compound
alkyl
reaction
radical
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710169305.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN106967042A (zh
Inventor
刘瑜
余官能
郑志国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Ausun Pharmaceutical Co Ltd
Original Assignee
Zhejiang Ausun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Ausun Pharmaceutical Co Ltd filed Critical Zhejiang Ausun Pharmaceutical Co Ltd
Priority to CN201710169305.9A priority Critical patent/CN106967042B/zh
Publication of CN106967042A publication Critical patent/CN106967042A/zh
Priority to US15/681,716 priority patent/US9988364B1/en
Priority to CN201780088821.7A priority patent/CN110461826B/zh
Priority to PT179015409T priority patent/PT3611171T/pt
Priority to PCT/CN2017/106348 priority patent/WO2018171173A1/zh
Priority to KR1020197030823A priority patent/KR102547559B1/ko
Priority to JP2019552046A priority patent/JP7098651B2/ja
Priority to US16/496,008 priority patent/US11697644B2/en
Priority to HUE17901540A priority patent/HUE068098T2/hu
Priority to EP24180985.4A priority patent/EP4417605A3/en
Priority to ES17901540T priority patent/ES2986115T3/es
Priority to HRP20241128TT priority patent/HRP20241128T1/hr
Priority to EP17901540.9A priority patent/EP3611171B1/en
Application granted granted Critical
Publication of CN106967042B publication Critical patent/CN106967042B/zh
Priority to JP2022002669A priority patent/JP7307823B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/24Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds
    • C07C209/26Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds by reduction with hydrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18Ethylenedioxybenzenes, not substituted on the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
CN201710169305.9A 2017-03-21 2017-03-21 依利格鲁司他的合成方法及其中间体化合物 Active CN106967042B (zh)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CN201710169305.9A CN106967042B (zh) 2017-03-21 2017-03-21 依利格鲁司他的合成方法及其中间体化合物
US15/681,716 US9988364B1 (en) 2017-03-21 2017-08-21 Process for synthesis of Eliglustat and intermediate compounds thereof
HUE17901540A HUE068098T2 (hu) 2017-03-21 2017-10-16 Eljárás eliglusztát és köztitermékei elõállítására
EP24180985.4A EP4417605A3 (en) 2017-03-21 2017-10-16 Method for synthesis of eliglustat and intermediate compounds thereof
PCT/CN2017/106348 WO2018171173A1 (zh) 2017-03-21 2017-10-16 依利格鲁司他的合成方法及其中间体化合物
KR1020197030823A KR102547559B1 (ko) 2017-03-21 2017-10-16 엘리글루스타트의 합성방법 및 그 중간체 화합물
JP2019552046A JP7098651B2 (ja) 2017-03-21 2017-10-16 エリグルスタット及びその中間化合物の合成方法
US16/496,008 US11697644B2 (en) 2017-03-21 2017-10-16 Process for synthesis of eliglustat and intermediate compounds thereof
CN201780088821.7A CN110461826B (zh) 2017-03-21 2017-10-16 依利格鲁司他的合成方法及其中间体化合物
PT179015409T PT3611171T (pt) 2017-03-21 2017-10-16 Método para a síntese de eliglustato e dos seus compostos intermédios
ES17901540T ES2986115T3 (es) 2017-03-21 2017-10-16 Método para la síntesis de eliglustat y compuestos intermedios del mismo
HRP20241128TT HRP20241128T1 (hr) 2017-03-21 2017-10-16 Postupak sinteze eliglustata i njegovih intermedijarnih spojeva
EP17901540.9A EP3611171B1 (en) 2017-03-21 2017-10-16 Method for synthesis of eliglustat and intermediate compounds thereof
JP2022002669A JP7307823B2 (ja) 2017-03-21 2022-01-12 エリグルスタット及びその中間化合物の合成方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710169305.9A CN106967042B (zh) 2017-03-21 2017-03-21 依利格鲁司他的合成方法及其中间体化合物

Publications (2)

Publication Number Publication Date
CN106967042A CN106967042A (zh) 2017-07-21
CN106967042B true CN106967042B (zh) 2020-08-14

Family

ID=59329206

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710169305.9A Active CN106967042B (zh) 2017-03-21 2017-03-21 依利格鲁司他的合成方法及其中间体化合物
CN201780088821.7A Active CN110461826B (zh) 2017-03-21 2017-10-16 依利格鲁司他的合成方法及其中间体化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780088821.7A Active CN110461826B (zh) 2017-03-21 2017-10-16 依利格鲁司他的合成方法及其中间体化合物

Country Status (10)

Country Link
US (2) US9988364B1 (https=)
EP (2) EP4417605A3 (https=)
JP (2) JP7098651B2 (https=)
KR (1) KR102547559B1 (https=)
CN (2) CN106967042B (https=)
ES (1) ES2986115T3 (https=)
HR (1) HRP20241128T1 (https=)
HU (1) HUE068098T2 (https=)
PT (1) PT3611171T (https=)
WO (1) WO2018171173A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106967042B (zh) 2017-03-21 2020-08-14 浙江奥翔药业股份有限公司 依利格鲁司他的合成方法及其中间体化合物
US20200306225A1 (en) * 2017-10-27 2020-10-01 Msn Laboratories Private Limited, R&D Center Stable n-((1r,2r)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl) octanamide (2r,3r)-2,3-dihydroxysuccinate premix and process for preparation thereof
WO2020020365A1 (zh) * 2018-07-27 2020-01-30 中国医学科学院药物研究所 制备光活依格鲁特的方法
CN110759885B (zh) * 2018-07-27 2021-10-22 中国医学科学院药物研究所 制备光活依格鲁特的方法
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
CN110256321B (zh) * 2019-06-12 2021-05-28 山东省医学科学院药物研究所(山东省抗衰老研究中心、山东省新技术制药研究所) (2r,3s,4s)-4-氨基-2-十四烷基吡咯烷-3-醇的制备方法及其应用
CN113893346B (zh) * 2020-06-22 2022-11-18 四川大学华西医院 Gcs抑制剂在制备治疗可卡因成瘾的药物中的用途
CN112125805B (zh) * 2020-09-11 2022-10-18 北京红惠新医药科技有限公司 水溶性厚朴酚衍生物及和厚朴酚衍生物和其中间体的制备方法、和相关的单羟基保护中间体
CN113880819B (zh) * 2021-09-18 2024-09-20 浙江大学医学院附属第一医院 立他司特的制备方法及其中间体化合物
CN114456089B (zh) * 2022-03-29 2023-05-23 南昌航空大学 一种路易斯酸促进的烯烃和肟酯与胺的三组分反应方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008399A1 (en) * 2001-07-16 2003-01-30 Genzyme Corporation Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
CN104557851A (zh) * 2015-02-10 2015-04-29 苏州明锐医药科技有限公司 依鲁司他的制备方法
CN105646442A (zh) * 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 一种依利格鲁司他的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068496A1 (en) 2015-10-20 2017-04-27 Dr. Reddy' S Laboratories Limited Improved process for the preparation of eliglustat and its salts
CN106349210A (zh) 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
CN106349310B (zh) 2016-08-26 2019-06-11 内蒙古嘉宝仕生物科技股份有限公司 甲氨基阿维菌素苯甲酸盐的制备方法
CN106967042B (zh) * 2017-03-21 2020-08-14 浙江奥翔药业股份有限公司 依利格鲁司他的合成方法及其中间体化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008399A1 (en) * 2001-07-16 2003-01-30 Genzyme Corporation Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
CN104557851A (zh) * 2015-02-10 2015-04-29 苏州明锐医药科技有限公司 依鲁司他的制备方法
CN105646442A (zh) * 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 一种依利格鲁司他的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
依利格鲁司特及西咪匹韦重要中间体的合成研究;杨斌;《中国优秀硕士学位论文全文数据库 工程科技I辑》;20170315(第03期);B016-1237 *

Also Published As

Publication number Publication date
ES2986115T3 (es) 2024-11-08
JP2022058564A (ja) 2022-04-12
CN106967042A (zh) 2017-07-21
EP3611171A1 (en) 2020-02-19
US11697644B2 (en) 2023-07-11
KR102547559B1 (ko) 2023-06-26
JP7307823B2 (ja) 2023-07-12
EP4417605A3 (en) 2025-03-12
HRP20241128T1 (hr) 2024-11-22
WO2018171173A1 (zh) 2018-09-27
JP7098651B2 (ja) 2022-07-11
US20200031808A1 (en) 2020-01-30
CN110461826A (zh) 2019-11-15
PT3611171T (pt) 2024-09-04
EP3611171B1 (en) 2024-06-12
KR20190140927A (ko) 2019-12-20
US9988364B1 (en) 2018-06-05
HUE068098T2 (hu) 2024-12-28
CN110461826B (zh) 2023-08-25
JP2020511508A (ja) 2020-04-16
EP4417605A2 (en) 2024-08-21
EP3611171A4 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
CN106967042B (zh) 依利格鲁司他的合成方法及其中间体化合物
TWI658042B (zh) 雜環化合物的合成
CN116964058A (zh) Kras g12d抑制剂及其在医药上的应用
KR20090045360A (ko) 4-치환된 페녹시페닐아세트산 유도체
TW200927123A (en) Novel compounds
JP2020511508A5 (https=)
WO2017066633A1 (en) Ep4 antagonists
TR201911245T4 (tr) Yeni hidroksamik asit türevi veya bunun tuzu.
CN103420893A (zh) 制备西洛多辛中间体的方法
JP5646706B2 (ja) C−グリコシド誘導体の製造方法
JP2018514572A (ja) オキシンドール化合物およびその医薬組成物
CN114957053A (zh) 一种氧代亚乙基类化合物或其药学上可接受的盐及其制备方法和应用、药物组合物及其应用
US20190315705A1 (en) Method for producing bicyclic compound
CN101107228A (zh) (z)-1-苯基-1-(n,n-二乙氨基羰基)-2-邻苯二甲酰亚氨甲基环丙烷的制造方法
CN102924548B (zh) 卡培他滨的合成方法
CN105566150B (zh) 阿利克伦的制备方法
WO2017133424A1 (zh) 一种1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)-环丙烷甲酸的制备方法及其中间体
CN112279849A (zh) 一种n-二氟甲基氮杂吲哚类化合物及其合成方法
CN105399668A (zh) 一种“一锅法”制备索拉菲尼的方法
CN106518939A (zh) 一种制备Solithromycin化合物的方法
CN102442947A (zh) 孟鲁司特钠中间体的制备方法
CN100569745C (zh) 制备坦舒乐欣的方法
WO2025033387A1 (ja) 糖脂質誘導体の製造法及びそれらの合成中間体並びにその結晶体
CN100582094C (zh) 3,4,5-三羟基哌啶生物碱的制备方法
CN119978009A (zh) 一种色瑞替尼衍生物、其制备方法、应用及药物

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant